Thiard News@F4F

@newsen.bsky.social

2 days ago

Lupin Receives FDA Approval for Dapagliflozin and Metformin Hydrochloride Tablets Lupin Limited has received FDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, expanding its pharmaceutical offerings.

Lupin Receives FDA Approval for Dapagliflozin and Metformin Hydrochloride Tablets #United_States #Mumbai #Lupin_Limited #Metformin #Dapagliflozin

Thiard News@F4F

@newsen.bsky.social

2 days ago

Lupin Limited Secures FDA Approval for Dapagliflozin Tablets in US Market Lupin Limited has announced that the U.S. FDA granted approval for its Dapagliflozin Tablets, marking a significant milestone in diabetes treatment options available in the US.

Lupin Limited Secures FDA Approval for Dapagliflozin Tablets in US Market #United_States #FDA_Approval #Naples #Lupin_Limited #Dapagliflozin

Thiard News@F4F

@newsen.bsky.social

1 week ago

Lupin Completes Strategic Acquisition of VISUfarma to Enhance Ophthalmology Portfolio Lupin has successfully finalized its acquisition of VISUfarma, significantly expanding its ophthalmology portfolio and reinforcing its European presence.

Lupin Completes Strategic Acquisition of VISUfarma to Enhance Ophthalmology Portfolio #India #Mumbai #ophthalmology #Lupin_Limited #VISUfarma

Thiard News@F4F

@newsen.bsky.social

1 week ago

Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio Lupin Limited has successfully finalized its acquisition of VISUfarma, enhancing its specialized ophthalmology offerings and boosting its European market presence.

Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio #India #Mumbai #pharmaceuticals #Lupin_Limited #VISUfarma

Thiard News@F4F

@newsen.bsky.social

1 week ago

Lupin Completes Acquisition of VISUfarma to Enhance Ophthalmology Portfolio Lupin Limited has successfully finalized its acquisition of VISUfarma B.V., strengthening its presence in the ophthalmology sector across Europe.

Lupin Completes Acquisition of VISUfarma to Enhance Ophthalmology Portfolio #India #Mumbai #ophthalmology #Lupin_Limited #VISUfarma

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Lupin's Tentative FDA Approval for Pitolisant Tablets Marks Key Milestone in Pharma Industry Lupin Limited has announced its tentative FDA approval for Pitolisant Tablets, strengthening its presence in the pharmaceutical market and aimed at improving patient health outcomes.

Lupin's Tentative FDA Approval for Pitolisant Tablets Marks Key Milestone in Pharma Industry #India #Mumbai #Lupin_Limited #Wakix® #Pitolisant_Tablets

Thiard News@F4F

@newsen.bsky.social

1 month ago

Vinita Gupta: Leading Change in Healthcare Accessibility and Affordability Vinita Gupta, CEO of Lupin, is named to CNBC's 2026 Changemakers List. Her dedication to accessible healthcare marks transformative changes in the pharmaceutical industry.

Vinita Gupta: Leading Change in Healthcare Accessibility and Affordability #India #Mumbai #Lupin_Limited #CNBC_Changemakers #Vinita_Gupta

Thiard News@F4F

@newsen.bsky.social

1 month ago

Lupin Limited Announces FDA Approval and U.S. Launch of Brivaracetam Oral Solution for Seizures Lupin Limited has received FDA approval for Brivaracetam Oral Solution, a treatment for seizures, and is now launching it in the U.S. market.

Lupin Limited Announces FDA Approval and U.S. Launch of Brivaracetam Oral Solution for Seizures #United_States #FDA_Approval #Naples #Lupin_Limited #Brivaracetam

Thiard News@F4F

@newsen.bsky.social

2 months ago

Lupin Introduces Topiramate Extended-Release Capsules to U.S. Market, Enhancing Treatment Options Lupin Limited has launched Topiramate Extended-Release Capsules in various dosages in the U.S., offering new treatment options for seizure disorders and migraines.

Lupin Introduces Topiramate Extended-Release Capsules to U.S. Market, Enhancing Treatment Options #United_States #Naples #Lupin_Limited #Topiramate #Trokendi_XR

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lupin Unveils Game-Changing Risperidone Injectable with Exclusive CGT in the U.S. Lupin Limited has launched a revolutionary Risperidone long-acting injectable, gaining exclusive CGT for 180 days in the U.S., marking a new era in treatment.

Lupin Unveils Game-Changing Risperidone Injectable with Exclusive CGT in the U.S. #United_States #Florida #Lupin_Limited #risperidone #PrecisionSphere

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lupin Limited Celebrates New Corporate Office Opening in Bridgewater, NJ Lupin Limited marks the grand opening of its corporate office in Bridgewater, NJ, showcasing its commitment to innovation and economic growth.

Lupin Limited Celebrates New Corporate Office Opening in Bridgewater, NJ #United_States #New_Jersey #Bridgewater #Lupin_Limited #Corporate_Office

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025 Lupin Limited is set to present critical Phase 1 data on LNP3693, a STING agonist, at the ESMO Congress 2025, highlighting potential advances in cancer treatment.

Lupin to Showcase Phase 1 Data for LNP3693 at ESMO Congress 2025 #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress Lupin Limited will showcase critical Phase I trial data for LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, highlighting its potential in oncology.

Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress #India #Mumbai #Lupin_Limited #ESMO_2025 #LNP3693

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin Lupin Limited is set to present data from its Phase 1 trial of LNP3693, a STING agonist, at the ESMO 2025 Congress in Berlin, showcasing its potential in treating advanced solid tumors.

Lupin to Present Phase 1 Data of LNP3693 at ESMO Congress 2025 in Berlin #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025 Lupin Limited announces the presentation of Phase-1 findings for LNP3693 at the ESMO Congress 2025, highlighting its potential in cancer treatment.

Lupin to Present Phase-1 Data on LNP3693 at ESMO Congress 2025 #India #Mumbai #Lupin_Limited #ESMO_Congress #LNP3693

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Unveils Strategic Partnership Program to Expand PrecisionSphere™ Injectable Platform Lupin Limited has launched a program aimed at enhancing the PrecisionSphere™ injectable platform's global reach. The initiative focuses on strategic partnerships, promising innovative health solutions.

Lupin Unveils Strategic Partnership Program to Expand PrecisionSphere™ Injectable Platform #India #Mumbai #Lupin_Limited #Nanomi_B.V. #PrecisionSphere

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Unveils Strategic Partnership Program to Expand Injectable Solutions Reach Lupin Limited has launched a strategic partnership initiative aimed at broadening the reach of its long-acting injectable platform, PrecisionSphere™, enhancing patient access.

Lupin Unveils Strategic Partnership Program to Expand Injectable Solutions Reach #India #Mumbai #Nanomi #Lupin_Limited #PrecisionSphere

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Launches New Strategic Partnership Program for Long-Acting Injectable Expansion Lupin Limited has announced a new strategic partnership program aiming to broaden the reach and utilization of its PrecisionSphere™ long-acting injectable platform, enhancing patient access globally.

Lupin Launches New Strategic Partnership Program for Long-Acting Injectable Expansion #India #Mumbai #Nanomi #Lupin_Limited #PricisionSphere

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Unveils Plans for New High-Tech Manufacturing Facility in Coral Springs, Florida Lupin is set to build a state-of-the-art pharmaceutical facility in Coral Springs, enhancing domestic production of critical respiratory medicines.

Lupin Unveils Plans for New High-Tech Manufacturing Facility in Coral Springs, Florida #United_States #Coral_Springs #Lupin_Limited #respiratory_medicines

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Expands Global Ophthalmology Footprint with VISUfarma Acquisition Lupin Limited has announced its acquisition of VISUfarma to enhance its global ophthalmology portfolio, gaining access to innovative products in a growing market.

Lupin Expands Global Ophthalmology Footprint with VISUfarma Acquisition #India #Mumbai #Lupin_Limited #VISUfarma #GHO_Capital

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Expands Its Global Ophthalmology Expertise with Strategic Acquisition of VISUfarma Lupin Limited takes a significant step in expanding its ophthalmology specialty business by acquiring VISUfarma, enhancing its product portfolio and market presence in Europe.

Lupin Expands Its Global Ophthalmology Expertise with Strategic Acquisition of VISUfarma #India #Mumbai #Lupin_Limited #VISUfarma #GHO_Capital

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Expands Global Reach in Ophthalmology with VISUfarma Acquisition Lupin Limited, a global pharmaceutical leader, enhances its presence in the ophthalmology market by acquiring VISUfarma, signaling a strategic expansion in Europe.

Lupin Expands Global Reach in Ophthalmology with VISUfarma Acquisition #India #Mumbai #Lupin_Limited #VISUfarma #GHO_Capital

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lupin Secures FDA Approval for Long-Acting Injectable Risperidone in the U.S. Lupin Limited has proudly announced the FDA's approval for their long-acting injectable risperidone, marking a significant milestone in its Nanomi platform.

Lupin Secures FDA Approval for Long-Acting Injectable Risperidone in the U.S. #USA #Naples #Nanomi #Lupin_Limited #risperidone

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lupin to Present Phase 1 Data on Novel PRMT5 Inhibitor LNP7457 at ASCO 2025 Lupin Limited will unveil results from its Phase 1a trial of LNP7457, a PRMT5 inhibitor, during the ASCO annual meeting, showcasing potential cancer treatment advancements.

Lupin to Present Phase 1 Data on Novel PRMT5 Inhibitor LNP7457 at ASCO 2025 #India #Chicago #PRMT5_Inhibitor #Lupin_Limited #LNP7457

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lupin and Honeywell Collaborate on Innovative HFO Technology for Inhalers Lupin and Honeywell are partnering to revolutionize asthma care with environmentally friendly inhalers using Honeywell's Solstice® Air technology, minimizing carbon impact.

Lupin and Honeywell Collaborate on Innovative HFO Technology for Inhalers #India #Honeywell #Mumbai #Lupin_Limited #Solstice_Air

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lupin and Honeywell Collaborate to Innovate Inhaler Technology with Eco-Friendly Solutions Lupin Limited plans to revolutionize inhaler technology by adopting Honeywell's Solstice® Air, aiming for sustainable respiratory care with minimal environmental impact.

Lupin and Honeywell Collaborate to Innovate Inhaler Technology with Eco-Friendly Solutions #India #Honeywell #Mumbai #Lupin_Limited #Solstice_Air

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lupin Partners with Honeywell to Innovate Inhaler Technology Using HFO Propellants Lupin Limited plans to leverage Honeywell's advanced HFO technology for next-generation inhalers, reducing environmental impact for asthma and COPD patients.

Lupin Partners with Honeywell to Innovate Inhaler Technology Using HFO Propellants #India #Honeywell #Mumbai #Lupin_Limited #Solstice_Air

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nanomi Recognized with CMO Award for Excellence in Drug Delivery Innovations Nanomi B.V., a subsidiary of Lupin Limited, has earned the prestigious CMO Award for its groundbreaking contributions in drug delivery, marking a significant milestone in healthcare innovation.

Nanomi Recognized with CMO Award for Excellence in Drug Delivery Innovations #Netherlands #Nanomi #Lupin_Limited #Oldenzaal #CMO_Award

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nanomi Receives Prestigious CMO Award for Leadership in Drug Delivery Innovations Nanomi B.V., a Netherlands-based subsidiary of Lupin Limited, has been awarded the CMO Award for Leadership in drug delivery during the DCAT week in New York. This recognition highlights their innovative contributions to the healthcare sector.

Nanomi Receives Prestigious CMO Award for Leadership in Drug Delivery Innovations #biopharmaceuticals #Netherlands #Nanomi #Lupin_Limited #Oldenzaal

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nanomi B.V. Earns CMO Award for Excellence in Drug Delivery Leadership Nanomi B.V. has been honored with the prestigious CMO Award in life sciences for innovation in drug delivery. This achievement reflects their commitment to advancing healthcare.

Nanomi B.V. Earns CMO Award for Excellence in Drug Delivery Leadership #Netherlands #Drug_Delivery #Lupin_Limited #Oldenzaal #Nanomi_B.V.